What is Clenpiq?
Clenpiq is an FDA-approved, low-volume bowel preparation medication combining sodium picosulfate (a stimulant laxative), magnesium oxide, and anhydrous citric acid (which form magnesium citrate, an osmotic laxative) used to cleanse the colon before colonoscopy in adults and children 9 years and older. 1
Mechanism of Action
Clenpiq works through dual mechanisms:
- Sodium picosulfate acts as a stimulant laxative by increasing peristaltic frequency and force in the colon
- Magnesium oxide and citric acid combine to form magnesium citrate, which acts as an osmotic laxative by retaining fluid in the colon 1, 2
The sodium picosulfate component is a prodrug that requires bacterial hydrolysis in the colon to form its active metabolite, 4'-dihydroxydiphenyl-(2-pyridyl)methane 2.
Dosing and Administration
Two bottles (doses) of Clenpiq are required for complete bowel preparation, administered as a split-dose regimen 1:
- First dose: Evening before colonoscopy
- Second dose: Morning of colonoscopy, completed at least 2 hours before procedure start
Each bottle contains 175 mL of ready-to-drink solution (no dilution needed). Patients must consume:
- Five or more 8-ounce cups of clear liquids after the first dose
- Four or more 8-ounce cups of clear liquids after the second dose
- Include balanced electrolyte solutions along with other clear liquids 1
Critical timing: Take oral medications at least 1 hour before starting Clenpiq. For tetracyclines, fluoroquinolones, iron, digoxin, chlorpromazine, or penicillamine, administer at least 2 hours before and not less than 6 hours after Clenpiq 1.
Efficacy
Clenpiq (sodium picosulfate + magnesium oxide + citrate) demonstrates similar bowel preparation quality to 2L PEG-based preparations when used in split-dose regimens 3. Recent trials show comparable rates of adequate bowel preparation between split-dose Clenpiq and split-dose 2L PEG-ELS with ascorbate 3.
The 2025 US Multi-Society Task Force guidelines confirm that sodium picosulfate + magnesium oxide + citrate is FDA-approved and effective for colonoscopy preparation 3. Split-dose administration is strongly recommended for all bowel preparations, as it significantly improves cleansing quality, particularly in the right colon 4.
Safety Profile and Contraindications
Absolute contraindications 1:
- Severe renal impairment (creatinine clearance <30 mL/minute)
- Gastrointestinal obstruction or ileus
- Bowel perforation
- Toxic colitis or toxic megacolon
- Gastric retention
- Hypersensitivity to any ingredient
Important Safety Concerns
Electrolyte disturbances are the primary safety consideration 3:
- Hypermagnesemia: Transient elevation occurs in 35% of patients at 5-12 hours post-ingestion, but values are only minimally elevated and resolve by 24 hours in patients with normal renal function 5
- Hyponatremia: Increased risk in patients ≥65 years old (absolute risk increase 0.05%, RR 2.4), associated with higher hospitalization rates but not with urgent CT head needs or death 3
- Hypokalemia and hypocalcemia: Occur but normalize by 24 hours 5
The hyperosmolar nature contraindicates use in patients with congestive heart failure, hypermagnesemia, and severe renal impairment 3.
Common Adverse Events
In adults (≥2%): nausea, headache, hypermagnesemia, abdominal pain, dehydration, and dizziness 1
In pediatrics ages 9-16 (>5%): nausea, vomiting, and abdominal pain 1
Clenpiq demonstrates better tolerability than high-volume PEG preparations, with less vomiting compared to PEG-ELS, though dizziness occurs more frequently 3. Patient acceptance is high, with excellent subjective satisfaction scores for ease of taking and taste 6.
Clinical Considerations
Adequate hydration is essential to prevent fluid and electrolyte abnormalities, arrhythmias, seizures, and renal impairment 1. Consider baseline and post-procedure laboratory assessments in high-risk patients, particularly those with:
- Pre-existing renal impairment
- Concomitant medications affecting renal function or electrolytes
- Age ≥65 years
- Cardiovascular disease 3
Syncope risk: Can result in serious outcomes including falls, head injuries, and fractures; emphasize adequate hydration 1.
Mucosal ulcerations: Consider this potential when interpreting colonoscopy findings in patients with known or suspected inflammatory bowel disease 1.
Comparative Effectiveness
Recent meta-analyses show that sodium picosulfate + magnesium citrate preparations have superior efficacy to PEG-ELS for volumes <4L and are better tolerated with higher completion rates and patient willingness to repeat the regimen 3. However, when compared specifically to 4L PEG-based regimens, the superiority in bowel preparation quality is no longer evident 3.
Split-dose Clenpiq is comparable to other low-volume preparations including 2L PEG with ascorbate and oral sulfate solutions in terms of adequate bowel preparation rates 3.